GEN Restaurant Group, Inc.
GENKGen Korean BBQ is an American chain of all-you-can-eat Korean barbecue restaurants mainly concentrated around the Western U.S. It opened in 2011, and has since grown to 43 locations as of 2024.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How GENK's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SUL-238 (1500 mg t.i.d.) film-coated tablets | Phase 2 | Parkinson's Disease (PD) | - | - |
Frequently asked questions
What is in GEN Restaurant Group, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in GEN Restaurant Group, Inc.'s (GENK) pipeline across Phase 2. Its lead program is SUL-238 (1500 mg t.i.d.) film-coated tablets (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is GEN Restaurant Group, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for GEN Restaurant Group, Inc. (GENK) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GENK biotech catalysts?→
Add GENK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow GEN Restaurant Group, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.